ERG Oncoprotein Expression in Prostate Cancer: Clonal Progression of ERG-positive Tumor Cells and Potential for ERG-based Stratification

Overview

Journal Prostate Cancer Prostatic Dis

Specialties Oncology
Urology

Date 2010 Jun 30

PMID 20585344

Citations 112

Authors

B Furusato

S-H Tan

D Young

A Dobi

C Sun

A A Mohamed

R Thangapazham

Y Chen

G McMaster

T Sreenath

G Petrovics

D G McLeod

S Srivastava

I A Sesterhenn

Affiliations

Soon will be listed here.

Abstract

Gene fusions prevalent in prostate cancer (CaP) lead to the elevated expression of the ERG proto-oncogene. ERG activation present in 50-70% of prostate tumors underscores one of the most common oncogenic alterations in CaP. Despite numerous reports of gene fusions and mRNA expression, ERG oncoprotein status in CaP still remains to be defined. Furthermore, development of ERG protein-based assays may provide a new dimension to evaluation of gene fusions involving diverse androgen-regulated promoters and the ERG protein-coding sequence. Through exhaustive evaluations of 132 whole-mount prostates (261 tumor foci and over 200 000 benign glands) for the ERG oncoprotein nuclear expression, we demonstrated 99.9% specificity for detecting prostate tumor cells using a highly specific anti-ERG monoclonal antibody. The ERG oncoprotein expression correlated well with fusion transcript or gene fusion in randomly selected specimens. Strong concordance of ERG-positive foci of prostatic intraepithelial neoplasia (PIN) with ERG-positive carcinoma (82 out of 85 sections with PIN, 96.5%) affirms the biological role of ERG in clonal selection of prostate tumors in 65% (86 out of 132) of patients. Conversely, ERG negative PINs were associated with ERG-negative carcinoma. Taken together, the homogeneous and strong ERG expression detected in individual tumors establishes the potential for ERG oncoprotein-based stratification of CaP.

Citing Articles

AR and YAP crosstalk: impacts on therapeutic strategies in prostate cancer.

Zheng G, Yan Z, Zou J, Zou X, Chai K, Zhang G Front Oncol. 2025; 15:1520808.

PMID: 39963114 PMC: 11830605. DOI: 10.3389/fonc.2025.1520808.

Exploring the efficacy of AMACR, ERG, and AR immunostains in prostatic adenocarcinoma and their association with novel grade groups.

Andarawi M, Otifi H, Hassan H, Yousif A, Mustafa S, Elsiddig S Eur J Histochem. 2025; 69(1).

PMID: 39931952 PMC: 11864098. DOI: 10.4081/ejh.2025.4172.

Frequent CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression.

Diossy M, Tisza V, Li H, Sahgal P, Zhou J, Sztupinszki Z NPJ Precis Oncol. 2024; 8(1):208.

PMID: 39294262 PMC: 11411125. DOI: 10.1038/s41698-024-00705-8.

Increased frequency of CHD1 deletions in prostate cancers of African American men is associated with rapid disease progression without inducing homologous recombination deficiency.

Szallasi Z, Diossy M, Tisza V, Li H, Sahgal P, Zhou J Res Sq. 2024; .

PMID: 38645014 PMC: 11030533. DOI: 10.21203/rs.3.rs-3995251/v1.

The potential role of the microbiota in prostate cancer pathogenesis and treatment.

Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M Nat Rev Urol. 2023; 20(12):706-718.

PMID: 37491512 DOI: 10.1038/s41585-023-00795-2.

References

LARKIN M, Blackshields G, Brown N, Chenna R, McGettigan P, McWilliam H . Clustal W and Clustal X version 2.0. Bioinformatics. 2007; 23(21):2947-8. DOI: 10.1093/bioinformatics/btm404. View

Carver B, Tran J, Gopalan A, Chen Z, Shaikh S, Carracedo A . Aberrant ERG expression cooperates with loss of PTEN to promote cancer progression in the prostate. Nat Genet. 2009; 41(5):619-24. PMC: 2835150. DOI: 10.1038/ng.370. View

Clark J, Merson S, Jhavar S, Flohr P, Edwards S, Foster C . Diversity of TMPRSS2-ERG fusion transcripts in the human prostate. Oncogene. 2006; 26(18):2667-73. DOI: 10.1038/sj.onc.1210070. View

Petrovics G, Liu A, Shaheduzzaman S, Furusato B, Furasato B, Sun C . Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcriptome. Oncogene. 2005; 24(23):3847-52. DOI: 10.1038/sj.onc.1208518. View

King J, Xu J, Wongvipat J, Hieronymus H, Carver B, Leung D . Cooperativity of TMPRSS2-ERG with PI3-kinase pathway activation in prostate oncogenesis. Nat Genet. 2009; 41(5):524-6. PMC: 2898503. DOI: 10.1038/ng.371. View

Klezovitch O, Risk M, Coleman I, Lucas J, Null M, True L . A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci U S A. 2008; 105(6):2105-10. PMC: 2538886. DOI: 10.1073/pnas.0711711105. View

Perner S, Mosquera J, Demichelis F, Hofer M, Paris P, Simko J . TMPRSS2-ERG fusion prostate cancer: an early molecular event associated with invasion. Am J Surg Pathol. 2007; 31(6):882-8. DOI: 10.1097/01.pas.0000213424.38503.aa. View

Barry M, Perner S, Demichelis F, Rubin M . TMPRSS2-ERG fusion heterogeneity in multifocal prostate cancer: clinical and biologic implications. Urology. 2007; 70(4):630-3. PMC: 3198826. DOI: 10.1016/j.urology.2007.08.032. View

Knudsen B, Allen A, McLerran D, Vessella R, Karademos J, Davies J . Evaluation of the branched-chain DNA assay for measurement of RNA in formalin-fixed tissues. J Mol Diagn. 2008; 10(2):169-76. PMC: 2259472. DOI: 10.2353/jmoldx.2008.070127. View

10.

Baltzinger M, Remy P . Xl erg: expression pattern and overexpression during development plead for a role in endothelial cell differentiation. Dev Dyn. 2000; 216(4-5):420-33. DOI: 10.1002/(SICI)1097-0177(199912)216:4/5<420::AID-DVDY10>3.0.CO;2-C. View

11.

Hameed O, Sublett J, Humphrey P . Immunohistochemical stains for p63 and alpha-methylacyl-CoA racemase, versus a cocktail comprising both, in the diagnosis of prostatic carcinoma: a comparison of the immunohistochemical staining of 430 foci in radical prostatectomy and needle biopsy.... Am J Surg Pathol. 2005; 29(5):579-87. DOI: 10.1097/01.pas.0000157936.93999.18. View

12.

Cerveira N, Ribeiro F, Peixoto A, Costa V, Henrique R, Jeronimo C . TMPRSS2-ERG gene fusion causing ERG overexpression precedes chromosome copy number changes in prostate carcinomas and paired HGPIN lesions. Neoplasia. 2006; 8(10):826-32. PMC: 1715930. DOI: 10.1593/neo.06427. View

13.

Ellett F, Kile B, Lieschke G . The role of the ETS factor erg in zebrafish vasculogenesis. Mech Dev. 2008; 126(3-4):220-9. PMC: 2844499. DOI: 10.1016/j.mod.2008.11.001. View

14.

Furusato B, Gao C, Ravindranath L, Chen Y, Cullen J, McLeod D . Mapping of TMPRSS2-ERG fusions in the context of multi-focal prostate cancer. Mod Pathol. 2007; 21(2):67-75. DOI: 10.1038/modpathol.3800981. View

15.

Bonaccorsi L, Nesi G, Nuti F, Paglierani M, Krausz C, Masieri L . Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results. J Endocrinol Invest. 2009; 32(7):590-6. DOI: 10.1007/BF03346514. View

16.

Mehra R, Han B, Tomlins S, Wang L, Menon A, Wasco M . Heterogeneity of TMPRSS2 gene rearrangements in multifocal prostate adenocarcinoma: molecular evidence for an independent group of diseases. Cancer Res. 2007; 67(17):7991-5. DOI: 10.1158/0008-5472.CAN-07-2043. View

17.

Zong Y, Xin L, Goldstein A, Lawson D, Teitell M, Witte O . ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci U S A. 2009; 106(30):12465-70. PMC: 2708977. DOI: 10.1073/pnas.0905931106. View

18.

Clark J, Cooper C . ETS gene fusions in prostate cancer. Nat Rev Urol. 2009; 6(8):429-39. DOI: 10.1038/nrurol.2009.127. View

19.

Kumar-Sinha C, Tomlins S, Chinnaiyan A . Recurrent gene fusions in prostate cancer. Nat Rev Cancer. 2008; 8(7):497-511. PMC: 2711688. DOI: 10.1038/nrc2402. View

20.

Sun C, Dobi A, Mohamed A, Li H, Thangapazham R, Furusato B . TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene. 2008; 27(40):5348-53. PMC: 7556723. DOI: 10.1038/onc.2008.183. View